Octapharma AG

Octapharma AG engages in the development, production, and distribution of plasma derivatives for treatment in coagulation disorders, immune disease, and intensive care and emergency medicine. Its products include virus-inactivated plasma for transfusion; and fractionation products, such as coagulation Factors VIII and IX for the treatment of haemophilia. The company also offers von Willebrand Factor concentrate, prothrombin complex concentrate, albumin for fluid resuscitation, and immunoglobulins for various indications, including immune deficiencies and autoimmune disease. Octapharma distributes its products through a network of direct sellers and distributor networks in Europe, Asia, the Middle East, Australia, New Zealand, South America, and North America. It has production facilities in Austria, France, Sweden, and Mexico. The company was founded in 1982 and is headquartered in Lachen, Switzerland.